SEC Tracker
Get the app

MBX Biosciences MBX

MBX Biosciences Biosciences appoints Peter Radovich as director

Item 5.02 Executive or director change

Form
8-K
Filed
Importance
Major
  1. Appointed on October 20, 2026
  2. Class I director until 2028 Annual Meeting
  3. Received 18,200 stock options
  4. Compensation per 2026 Non-Employee Director Policy

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when MBX Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Heron Therapeutics HRTX public float $235M, Jun 30, 2025
  2. Aldeyra Therapeutics ALDX public float $232M, Jun 30, 2025
  3. Annexon ANNX public float $244M, Jun 30, 2025
  4. Sagimet Biosciences SGMT public float $228M, Jun 30, 2025
  5. DBV Technologies DBVT public float $251M, Jun 30, 2025